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Abstract: Preterm birth is the major cause of perinatal morbidity and mortality in the developed 
world, and spontaneous preterm labor is the commonest cause of preterm birth. Interventions 
to treat women in spontaneous preterm labor have not reduced the incidence of preterm births 
but this may be due to increased risk factors, inclusion of births at the limits of viability, and 
an increase in the use of elective preterm birth. The role of antibiotics remains unproven. In the 
largest of the randomized controlled trials, evaluating the use of antibiotics for the prevention 
of preterm births in women in spontaneous preterm labor, antibiotics against anaerobes and 
bacterial vaginosis-related organisms were not included, and no objective evidence of abnormal 
genital tract flora was obtained. Atosiban and nifedipine are the main tocolytic agents used to 
treat women in spontaneous preterm labor, but atosiban is the tocolytic agent with the fewest 
maternal – fetal side effects. A well conducted randomized controlled trial comparing atosiban 
with nifedipine for their effectiveness and safety is needed.
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Introduction
Spontaneous preterm labor (SPTL) – the onset of regular, painful, synchronous uterine 
contractions before 37 completed weeks of gestation – is a syndrome caused by a 
multifactorial etiology such as infection/inflammation, uteroplacental ischemia or 
hemorrhage, uterine overdistention, stress, and immunologically related conditions.1 
SPTL is the most common cause of antenatal hospitalization,2 and of all preterm births 
(PTBs), about 40% to 50% are related to SPTL.3,4 In contrast to preterm premature 
rupture of the membranes and iatrogenic PTB, about 32% of all SPTL is associated 
with intra-amniotic infection (IAI).5 This article reviews the management of SPTL 
and the role of tocolytics.
Diagnosis of SPTL
The accurate diagnosis of SPTL is difficult. Fetal fibronectin (FFN), a glycoprotein 
found in the chorioamniotic membranes, decidua and cytotrophoblast is elevated 
in cervicovaginal secretions of women who deliver preterm.6 A multicenter trial of 
763 women considered to be in SPTL, with a mean gestational age at sampling of 
30.3 ± 3.0 weeks, evaluated the negative and positive predictive values of FFN for 
PTB. The mean gestational age at delivery was 38.4 ± 2.6 weeks, and at least 80% 
of these women remained undelivered up to 7 days later, irrespective of their FFN 
status.6 The negative predictive value of the FFN test far exceeds the positive predictive 
value. A meta-analysis of 27 studies using cervicovaginal FFN as a marker for preterm Therapeutics and Clinical Risk Management 2010:6 192
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delivery showed a low sensitivity for PTB occurring at less 
than 34 weeks’ gestation.7 A Cochrane systematic review on 
the use of FFN testing for reducing the risk of PTB showed 
that management of women in SPTL, based on knowledge 
of FFN results versus no knowledge, significantly decreased 
the risk of PTB.8 It remains uncertain which interventions 
are most useful when a positive FFN test is obtained, but 
length of hospital stay might be reduced and unnecessary 
tocolytic therapy and in utero transfer prevented if a negative 
FFN is obtained. The combination of positive FFN test, and 
the transvaginal ultrasound scan (TVUSS) of women with a 
short cervical length (30 mm) may identify those women 
who may benefit from interventions such as antibiotics and 
tocolytics which may reduce PTB.9–11
Infection and PTL
Chorioamnionitis is often subclinical, and requires 
amniocentesis to establish the diagnosis.12,13 Intraamniotic 
inflammation, defined as negative amniotic fluid (AF) 
culture with elevated levels of AF interleukin (IL)-1-α, 
IL 1-β, IL-6, IL-8, tumor necrosis factor-alpha (TNF-α) 
and IAI (positive AF culture) are both associated with an 
increased risk of adverse outcomes when compared with 
idiopathic SPTL.14–21 These include clinical chorioamnionitis, 
funisitis, neonatal respiratory distress syndrome (RDS), neo-
natal pneumonia, intraventricular hemorrhage (grade II), 
bronchopulmonary dysplasia and periventricular leucomalacia, 
and cerebral palsy.5,22–27
Antibiotics used in SPTL
Randomized placebo-controlled trials of the use of antibiotics 
for the treatment of SPTL have yielded conflicting results. 
The inclusion of antibiotics (clindamycin or metronidazole) 
which have activity against anaerobes and bacterial 
vaginosis (BV)-related organisms resulted in prolongation 
of pregnancy.28–30 Using a combination of ampicillin and 
metronidazole,28 Svare et al demonstrated that there was a 
significant prolongation of pregnancy (admission to delivery 
47.5 days versus 27 days, P  0.05) and decreased incidence 
of preterm birth (42% versus 65% P  0.05). There was no 
significant effect on maternal and neonatal infection. Norman 
et al used ampicillin and metronidazole and showed that 
pregnancy was prolonged by at least 7 days compared to 
placebo (63% versus 37%, P = 0.03) and neonatal morbidity 
was also decreased.29 McGregor et al used clindamycin, and 
detected a statistically significant prolongation of pregnancy 
in the treated group compared to placebo (35 days versus 
25 days P = 0.02).30
Oracle II randomized 6295 women into 4 groups – 
erythromycin only, co-amoxiclav only, combination of eryth-
romycin and co-amoxiclav, and placebo. The primary 
outcome measure was a composite of neonatal death, chronic 
lung disease or major cerebral abnormality on ultrasound 
before discharge from hospital. None of the antibiotics used 
showed any reduction in the composite outcome compared 
to placebo. There was no statistically significant difference 
in the prolongation of pregnancy between the four groups,31 
but the antibiotics used are not active against BV-related 
organisms,32–34 and are not recommended for the treatment 
of BV.35 In addition, no objective measure of abnormal 
colonization was used, and women with signs of infection 
were excluded. It is likely therefore, that a minority of 
women given antibiotics had any infection which needed 
correction. The median gestational age at delivery within the 
four groups was beyond 38 completed weeks which raises the 
question whether the women recruited were really in SPTL. 
In addition, other trials which did not use antibiotics which 
are active against BV related organisms and anaerobes have 
not shown any benefit.36–41 A Cochrane systematic review 
of eleven trials on the use of antibiotics for inhibiting PTL 
concluded that antibiotic use showed no benefit,42 partly 
because of small numbers of women included in the trials 
which used clindamycin or metronidazole compared to 
trials which did not use them, and mainly the overwhelming 
weighting of Oracle Π.
Antenatal glucocorticoids and PTL
Administration of a single course of antepartum glucocor-
ticoids to women in SPTL at risk of PTB between 23 and 
33 weeks gestation has been proven to reduce the incidences 
of neonatal RDS, intraventricular hemorrhage, neonatal 
sepsis, and need for admission to neonatal intensive care 
unit, necrotizing enterocolitis, and neonatal death.43 However, 
antenatal exposure to glucocorticoids might result in insulin 
resistance when the offspring reach adulthood.44 The benefit 
observed on the reduced incidence of neonatal RDS does not 
last beyond 7 days, which supports the importance of accurate 
diagnosis of SPTL. Repeat courses of antepartum gluco-
corticoids should be avoided since they can be associated 
with increased risk of small for gestational age, cesarean 
section,45 and suppression of the maternal and neonatal 
hypothalamic–pituitary–adrenal (HPA) axis.46,47 But the 
Cochrane review on repeat courses of antepartum glucocor-
ticoids showed a reduction in occurrence and severity of any 
neonatal lung disease, and serious infant morbidity.45 In a 
retrospective analysis of 713 infants (369 and 134 singleton Therapeutics and Clinical Risk Management 2010:6 193
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preterm infants delivered at 34 and 35 weeks gestation 
respectively, and 210 multiple gestation) whose mothers 
were exposed to single or multiple courses of antenatal 
corticosteroids (2–12 courses), a significant reduction in 
the head circumference (4.6 ± 1.9 mm) was observed in 
the multiple course group.48 A cohort of 541 very preterm 
infants from singleton pregnancies between 3 and 6 years 
of age were evaluated, using physical, cognitive, and 
psychological assessments. Three or more courses of ante-
natal corticosteroids were associated with increased rates 
of aggressive/destructive, distractible, and hyperkinetic 
behavior. The rate of cerebral palsy was, however, reduced.49 
Nevertheless, repeat courses of antepartum glucocorticoids 
should be avoided, and the single course should be selective 
and optimized.
Pathophysiology/biochemical 
triggers of PTL
The precise mechanism of labor in women remains incom-
plete clinically, endocrinologically and biochemically. 
Relatively increased plasma levels of corticotrophin releasing 
hormone – a peptide produced by the placenta – is associ-
ated with increased risk of PTBs, but this observation is not 
specific to SPTL.50–54 Detection of an early surge or increased 
levels of salivary estriol is also associated with SPTL, but this 
surge can occur about 3 weeks before the onset of SPTL.51
Experiments on parturition in sheep show that activation 
of the fetal pituitary adrenal axis results in increased fetal 
cortisol secretion. Cortisol leads to activation of p450 
dependent placental 17 alpha hydroxylase and 17–20 lyase 
enzymes to cause conversion of C21 to C18 steroids.56 
Maternal estradiol levels rise, and progesterone levels fall, 
and this change in estrogen: progesterone ratio leads to 
increased production of prostaglandins (PGs). Consequently, 
there is cervical ripening and increased activation of oxytocin 
receptors, leading to myometrial contractility. However, 
neither the induction of the placental p450 enzymes nor 
the fall in progesterone levels has been demonstrated in 
humans. It is possible that the lack of expression in humans 
of the placental p450 C17 enzymes serves to maintain the 
placental production of progesterone, which is reponsible for 
uterine quiescence and regulation of uterine activity during 
pregnancy.
Ovine and primate parturition studies show that increased 
levels of intrauterine cortisol, of maternal, fetal or the 
fetoplacental origin induce the expression of PG synthase 
type 2 (PGHS-2) in the amniochorion, and the supression 
of the NAD+ – dependent PG dehydrogenase in the amnion 
predominantly from epithelial cells, and to a lesser extent 
mesenchymal cells. As a result, there is increased production 
of PGE-2,58 and the increased activity of the fetal HPA axis 
leads to increased production of estriol which activates the 
PGHS-2 in maternal endometrial epithelium leading to 
increased levels of PGF2-α.57,59–61
In vitro studies on the regulation of PGHS-2 activity by 
glucocorticoids in the amnion have yielded conflicting results. 
Dexamethasone increases the PGHS-2 activity in confluent 
amnion cell cultures,62 and has no effect on PGHS-2 activity 
in freshly cultured amnion cells.63 In addition, dexamethasone 
suppressed cytokine induced PGHS-Π expression and 
activity in amnion cells by blocking transcription factor 
binding at the nuclear factor kappa beta (NF-κβ) and CRE 
5′ promoter sequences of the PGHS-2 gene.64
The role of progesterone
The suppression of progesterone receptors (PR) – effectively 
a functional withdrawal of progesterone – is also linked to 
the initiation of labor in humans. Two types of PR (A and B) 
are expressed in the human myometrium at term. It is the 
expression of PR-A mRNA, relative to PR-B mRNA that 
leads to functional withdrawal of progesterone.65 In vitro 
studies in mice demonstrate increased transcriptional 
activities of NF-κβ, in response to inflammatory cytokines 
such as IL-1β produced by fetal macrophages. Activation of 
fetal macrophages is believed to be due to secretion into the 
AF of major lung surfactant protein A and the final effect of 
these activities is supression of the PR.66
In an in vitro study of human tissue, Allport et al67 showed 
that increased NF-κΒ transcriptional activity leads to activa-
tion of the cyclooxygenase (COX) enzyme in the amnion. 
Two isoforms, one constitutive (COX-1) and the other 
inducible (COX-2) exist, but in human labor it is the COX-2 
enzyme that converts free arachidonic acid (produced from 
glycophospholipids in the cell membrane by increased 
phospholipase activity) into the PG precursors – PGH-2 and 
PGG-2.68,69 Triggers such as increased cortisol from maternal 
or fetal stress and/or inflammatory cytokines lead to increased 
production of PGs which override uterine quiescence, leading 
to functional withdrawal of progesterone.
Role of oxytocin
Coupling of oxytocin (OT), endothelin or prostanoid receptors 
with the enzyme phosholipase C beta (PLC-β) through the 
G protein coupled receptors (the most abundant receptors in 
the uterus) hydrolyzes OT sensitive phosphatidylinositol 4, 
5 bisphosphate (PIP2) in the cell membrane.58 This process Therapeutics and Clinical Risk Management 2010:6 194
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generates two secondary messengers – inositol 1, 4, 5 
triphosphate (IP3) and diacyl glycerol. IP3, coupled with 
specific receptors, releases stored intracellular calcium from 
the sacroplasmic reticulum. Production of IP3 may further 
induce influx of calcium (Ca2+) from the extracellular space 
through voltage gated channels.70 Activated myosin light 
chain kinase, under the influence of released intracellular 
calcium – calmodulin complexes, causes phosphorylation 
of myosin which then interacts with actin to cause uterine 
contraction. Dephosphorylation of myosin by myosin 
phosphatase leads to uterine relaxation.58,70
The Rho kinases, which belong to the family of G-proteins, 
also cause uterine contractions by inhibiting myosin 
phosphatase activity, which leads to calcium sensitization.71 
In contrast, coupling of β2-adrenergic and prostanoid 
receptors with the enzyme adenylcyclase (AC), possibly 
through G-protein coupled receptors, lead to production of 
cyclic nucleotides (cAMP and cGMP) and promotes uterine 
relaxation.58,72 Phosphodiesterase (PDE)-4, an isozyme 
of PDE predominantly expressed in the pregnant uterus, 
inhibits cAMP production, but progesterone promotes AC 
and inhibits PDE-4 activity.73 Summary of some of these 
biochemical events leading to PTL are shown in Figure 1.
Role of tocolytics – atosiban
OT is a potent uterotonic hormone that is secreted from the 
posterior pituitary gland. Although increased levels of OT 
are not evident during labor, the uterine contractile effect 
of oxytocin relies on activated OT receptors in the presence 
of increased estrogen and PG production.74 Atosiban is a 
nonapeptide, desamino-OT analogue, and a competitive 
vasopressin/oxytocin receptor antagonist (VOTra).75–78 
Atosiban inhibits the OT-mediated release of IP3 from the 
myometrial cell membrane.75 As a result, there is reduced 
release of intracellular, stored calcium from the sacroplasmic 
reticulum of myometrial cells, and reduced influx of Ca2+ 
from the extracellular space through voltage gated channels. 
In addition, atosiban suppresses OT-mediated release of PGE 
and PGF from the decidua.79,80
Phase II and III studies
Peak plasma concentrations of atosiban was achieved at 
2 to 8 minutes following intravenous (IV) administration 
(10 nmol/kg body weight) compared to peak concentration 
at 10 to 45 minutes following intranasal administration 
of atosiban at 100 nmol/kg body weight.81 Goodwin et al 
showed that following IV infusion of atosiban (300 µ/min) 
in women between 20 and 36 weeks’ gestation, and in whom 
contractions were absent for 6 hours or maximum infusion 
length of 12 hours, plasma atosiban concentrations reached 
steady state within 1 hour of the start of IV infusion.82 The 
decrease in uterine activity in the first 4 hours of IV infusion 
was directly proportional to the duration of infusion. At the 
completion of infusion, plasma atosiban levels declined in 
a bi-exponential manner with initial and terminal half lives 
of 13 ± 3 and 102 ± 18 minutes, respectively. In a phase II 
randomized placebo controlled trial of the effect of atosiban 
on premature uterine activity (20 to 36 weeks gestation), 
a 2-hour infusion of atosiban led to a statistically significant 
decline in the frequency of uterine contractions, suggesting 
that OT plays a role in the maintenance of PTL. The only 
adverse outcome reported in the atosiban group was nausea 
and vomiting in one patient.83 In a phase III randomized 
controlled trial of the effect of atosiban on PTL (20 to 
34 weeks), which allowed tocolytic rescue if after 1 hour of 
atosiban or placebo infusion, premature labor continued, the 
primary end-point was the time to delivery or therapeutic fail-
ure (progression of labor requiring an alternative tocolytic). 
There was no statistically significant difference between the 
two groups for the primary end-point. The secondary end-
points were the proportions of women who were successfully 
treated at 24 hours, 48 hours and 7 days after commencing ato-
siban or placebo infusion. The proportions were significantly 
higher in the atosiban group: 73% versus 58% at 24 hours 
(P  0.001), 67% versus 56% at 48 hours (P = 0.008), and 
62% versus 49% at 7 days (P = 0.003). Compared to placebo, 
the effect of atosiban on prolongation of pregnancy up to 
7 days was more evident in pregnancies 28 weeks com-
pleted weeks of gestation; 65% versus 48%, and 51% versus 
59% at 28 weeks.84 These findings emphasize the fact that 
VOTras play a role in the maintenance of SPTL, yet other 
mechanisms are also involved. The perinatal mortality rate 
was 2.1% in the atosiban group, compared to 1.4% in the pla-
cebo group with or without tocolytic rescue.84 However, the 
randomization was not stratified according to gestational age, 
which resulted in an excess of extremely premature infants 
at a more advanced stage of labor in the atosiban group, and 
the Cochrane Review85 has been criticized for their use of 
these data.77 In a randomized controlled trial of women who, 
after successful treatment with atosiban, had a maintenance 
subcutaneous infusion of atosiban or placebo, the use of 
atosiban resulted in a statistically significant prolongation of 
uterine quiescence, compared to placebo (median of 32.6 days 
versus 27.6 days). Women in the atosiban group had higher 
incidence injection site reactions (70% versus 48%) during 
the maintenance treatment.86Therapeutics and Clinical Risk Management 2010:6 195
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Worldwide comparative trial  
of atosiban versus beta-agonists
A worldwide, multinational, multicenter, double-dummy, 
comparative controlled study compared the effectiveness 
and safety of atosiban with conventional beta-agonist 
therapy (ritodrine, salbutamol or terbutaline) in the treatment 
of SPTL. Alternative tocolytic therapy could be used, if 
there were unacceptable side effects or if labor progressed. 
The methodology also permitted re-treatment in cases in 
which tocolysis had been initially successful provided the 
patient still fulfilled the protocol requirements. The study 
showed that atosiban was as effective as the beta-agonists 
in delaying delivery for 48 hours or 7 days. The need for 
rescue therapy was significantly reduced in the atosiban 
group compared with the beta-agonist group, at 48 hours 
and 7 days after initiation of tocolytic therapy. Maternal side 
effects, especially cardiovascular adverse events, occurred 
10 times more frequently in the beta-agonist group (8.3% 
versus 81.2%, P  0.001).and there was a 15-fold increased 
need for discontinuation of therapy due to unacceptable side 
effects. There was no statistically significant difference in 
the perinatal morbidity and mortality rates.87
Atosiban versus nifedipine
A meta-analysis using a “virtual” indirect comparison 
of atosiban versus the calcium channel blocker (CCB) 
nifedipine, included 9 randomized trials evaluating the 
effectiveness of nifedipine versus beta-agonists (different 
dosage, route and release formulation of nifedipine were 
used), and four trials of atosiban versus beta-agonists and 
concluded that the use of nifedipine was associated with 
a significant reduction in respiratory distress syndrome 
↑ Corticotrophin releasing hormone (CRH) levels 
↓
Progesterone receptor (PR) withdrawal  
↓
↑Oxytocin (OT) receptor expression 
↓
↑OT and OT receptor coupling 
↓
↑PG E2,PG F and free intracellular calcium
↓
Inflammatory cytokines – interleukin (IL)-1β
↓
↑ Nuclear factor κB(NF-κB) activity/ ↓PR expression 
↓
↑ Cyclooxygenase (COX) 2 enzyme activity 
↓
↑ Prostaglandin (PG) H2, G2
↓
↑ PG E2,PG F
↓
Uterine contractions
Uterine contractions 
Figure 1 Flow chart of biochemical events leading to preterm labor.Therapeutics and Clinical Risk Management 2010:6 196
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compared to atosiban. However, the number of women 
who remained undelivered by 48 hours was not statistically 
significantly different between the two groups.88 The true 
effect of randomization can be lost when comparing the 
effectiveness of two tocolytics in this indirect way, and 
the authors acknowledged the shortcomings of such an 
analysis and that a number of assumptions were made in the 
comparisons. A small interventional randomized controlled 
trial, of 63 women, comparing atosiban with nifedipine for 
the treatment of SPTL (24 weeks to 35 weeks gestation) 
permitted tocolytic rescue after 1 hour for failed tocolysis by 
the assigned drug. Tocolytic agents were administered until 
uterine quiescence was achieved, and maintenance tocolytic 
regimes were not specified. The main outcome measure 
was the proportion of women who did not deliver, or who 
required alternative tocolytic therapy to avoid side effects 
48 hours and 7 days after initiation of treatment. The study 
showed that there was no statistically significant difference 
between the two groups in delay of delivery for 48 hours up 
to 7 days. There was no statistically significant difference 
between the groups in the need for rescue tocolytic therapy. 
Nifedipine achieved uterine quiescence faster than atosiban 
(mean of 2.2 hours ± 0.93 versus 4.2 hours ± 1.1). Nausea 
occurred more frequently in the atosiban group. Headache, 
flushing, palpitation and hypotension were significantly 
increased in the nifedipine goup. Perinatal and neonatal 
outcomes were not significantly different between the 
groups.89 Another randomized controlled trial of 80 women, 
compared the efficacy of atosiban and nifedipine for the 
delay of delivery in women with PTL between 26 weeks and 
34 completed weeks of gestation. Atosiban was as effective 
as nifedipine for delay of delivery for 48 hours and 7 days, 
and with minimal maternal side effects. Rescue tocolytic and 
maintenance therapy were not part of the protocol. Hypoten-
sion (27.5%), palpitations (7.5%) and maternal tachycardia 
(7.5%) were reported in the nifedipine group and none (0%) 
in the atosiban group.90
Adverse effects of tocolytics
The posterior pituitary hormones, OT and arginine 
vasopressin, differ in structure by only two amino acids, 
and atosiban influences physiological effects of arginine 
vasopressin on the feto–maternal cardiovascular and 
renal systems.91 In late-gestation sheep, the administration 
of atosiban for 1 hour failed to induce fetomaternal 
cardiovascular changes.92 IV atosiban (300 µg/min) used in 
women scheduled for elective cesarean section demonstrated 
no significant effect on the umbilical cord blood gases, and 
maternal hematocrit.93 In contrast Blea et al found that in 
pregnant ewes, IV nifedipine was associated with fetal 
hypoxia and acidosis.94 There are also concerns with respect 
to the number of published reports of adverse feto–maternal 
events after the use of CCBs, compared to the use of atosi-
ban.95–107 In children aged 9 to 12 years who were exposed to 
nifedipine in utero compared to others with in utero exposure 
to ritodrine, measures of behavioural–emotional problems, 
motor function, parenting problems and education failed 
to demonstrate any significant difference between the two 
groups. The same comparison is needed to evaluate the 
long-term outcomes in children exposed to atosiban in utero, 
compared to nifedipine.108
For the treatment of SPTL, a complete course of atosiban 
is much more expensive than that of nifedipine.109 There is 
no doubt that a well conducted randomized controlled trial 
of atosiban versus nifedipine is needed.110
Conclusion
PTL is the most common event leading to PTB, but the 
prevention of SPTL remains challenging for clinicians. 
Accurate prediction of PTB in women admitted with 
threatened preterm labor remains difficult. Compared to 
traditional clinical methods, the combination of TVUSS 
and FFN may identify women who are in SPTL, and who 
are at increased risk of PTB, but further research is needed 
to identify factors that have better positive predictive values. 
The role of antibiotics for the prevention of PTB in women 
in SPTL remains unproven, but this should not be confused 
with prophylactic antibiotics given to women with abnormal 
genital tract colonization in early pregnancy. Studies that 
identify women with subclinical IAI may reveal women 
who are more likely to benefit from appropriate antibiotic 
administration. Tocolytic therapy is relatively ineffective in 
SPTL because of infection, and should be reserved for those 
in SPTL, of no obvious infective etiology. Compared to beta-
agonists and CCBs, atosiban has the fewest maternal and 
fetal side effects. Unlike CCBs, atosiban has proven benefit 
over placebo, and is at least as effective as other tocolytics. 
The role of atosiban for the prevention of PTB in women 
with SPTL without subclinical IAI, and in gestations when 
VOTra are well established (28 weeks’ gestation) needs 
further evaluation. Such study should include protocols to 
identify women likely to be in SPTL using FFN and TVUSS 
of cervical length.
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